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Introduction
Despite significant progress in the understanding of com-
plex mechanisms of malignant tumour pathogenesis and
treatment improvements ovarian cancer remains the le-
ading cause of death of women with tumours of the geni-
tal tract [1]. The high fatality ratio associated with ovarian
cancer is linked to the lack of recognisable pattern of
symptoms in the early stage. About 60-70% of women
with ovarian cancer are diagnosed as advanced stage dise-
ase [2]. Both surgery and chemotherapy play major roles
in the treatment of ovarian cancer. The aim of primary
surgery is to stage the disease and to remove, optimally,
all tumour mass. Although this is possible in early cancer
of the ovary, it becomes less achievable as the tumour
spreads throughout the abdominal cavity. Over the past
20 years, maximum cytoreductive surgery has been ad-
vocated on the premise that women with minimal residu-
al disease have a better prognosis than those with bulky
disease [2]. Cytoreductive surgery is commonly associated
with tissue and vascular damage with the release of blood
clotting activators [3]. From a wide spectrum of coagula-
tion abnormalities associated with solid tumours inclu-
ding ovarian cancer, disseminated intravascular coagu-
lation (DIC) is diagnosed in about 20-70% of patients
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Cytoreductive surgery plays a major role in the treatment of advanced carcinoma of the ovary. The procedure is frequently as-
sociated with a significant perioperative blood loss and tissue damage which, in some cases, might lead to initiation of life thre-
atening pathologic clotting and fibrinolysis reactions. The authors describe a case of successful treatment of massive intra-ab-
dominal haemorrhage complicating debulking surgery for advanced ovarian cancer with activated recombinant factor VIIa
(NovoSeven, Novo Nordisk). After administration of NovoSeven in two doses of 20 µg/kg the patient fully recovered with no
further blood loss and complete restoration of hemostasis. In conclusion, we suggest that activated recombinant factor VIIa
is an effective haemostatic agent which can be used for the treatment of severe intra-abdominal haemorrhage which has fa-
iled to respond to conventional therapy.
Zastosowanie rekombinowanego czynnika krzepni´cia FVIIa w leczeniu ci´˝kiego krwotoku dootrzewnowego
u chorej po rozleg∏ej operacji cytoredukcyjnej z powodu zaawansowanego raka jajnika – opis przypadku
Chirurgia cytoredukcyjna stanowi podstaw´ leczenia zaawansowanego raka jajnika. Towarzyszàca tego typu operacjom
utrata krwi oraz rozleg∏e uszkodzenia tkanek mogà wyzwoliç patologiczne procesy wykrzepiania i fibrynolizy, które w niektó-
rych sytuacjach mogà stanowiç bezpoÊrednie zagro˝enie ˝ycia chorej.
Przedstawiono szczegó∏owy opis przypadku skutecznego zastosowania rekombinowanego czynnika VIIa u chorej z ci´˝kim
krwawieniem dootrzewnowym, po operacji cytoredukcyjnej, wykonywanej z powodu zaawansowanego raka jajnika. U cho-
rej bez pierwotnych zaburzeƒ uk∏adu krzepni´cia krwi zastosowano dwukrotnie preparat NovoSeven w dawce 20 µg/kg,
uzyskujàc zatrzymanie krwawienia zagra˝ajàcego ˝yciu. Korzystny efekt dzia∏ania tego preparatu wskazuje na mo˝liwoÊç roz-
wa˝enia jego u˝ycia w przypadku ci´˝kich krwawieƒ, niemo˝liwych do opanowania klasycznymi metodami.
Key words: recombinant factor VIIa, intra-abdominal haemorrhage, ovarian cancer, DIC
S∏owa kluczowe: rekombinowany czynnik krzepni´cia krwi VIIa, krwotok dootrzewnowy, rak jajnika, DIC
Department of Gynaecologic Oncology
1 Department of Clinical Biochemistry
The Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology, Warsaw, Poland
310
[3]. In most cases DIC presents as a chronic sub-clinical
disorder detected by laboratory tests. Overt DIC, with
consumption of platelets and clotting factors and resultant
acute bleeding, is a life-threatening condition which requ-
ires immediate transfusion of blood or blood products
like fresh frozen plasma, cryoprecipitate or platelet con-
centrates.
The introduction of activated recombinant factor
VII (rVIIa) (NovoSeven; Novo Nordisk) has been a signi-
ficant advancement in the management of patients with
congenital factor VII deficiency, haemophilia A and B
with acquired coagulation inhibitors, thrombocytopenia
and platelet function disorders [4].
Recently published reports confirm its efficacy in
controlling severe haemorrhage after gynaecologic, urolo-
gic, gastrointestinal and brain surgery in patients without
pre existing coagulation disorders [4].
We report the successful use of rVIIa in the treat-
ment of severe intra-abdominal haemorrhage complica-
ting cytoreductive surgery for advanced ovarian cancer.
Case report
A 40-year old woman presented to a regional hospital in
January 2001 because of ascites and pelvic mass. The pa-
tient underwent explorative laparotomy with biopsies ob-
tained from the ovarian tumours and omentum. After
microscopic examination the diagnosis of stage IIIc mode-
rately differentiated serous adenocarcinoma of the ovary
was established. The patient was referred to the Depart-
ment of Gynecologic Oncology of the Maria Sklodow-
ska-Curie Memorial Cancer Center and Institute of On-
cology, where she received six cycles of chemotherapy
consisting of paclitaxel 170 mg/m2 and cisplatin 70 mg/m2.
A partial response (PR) was achieved after completion of
adjuvant treatment. After detailed clinical evaluation sup-
ported by imaging techniques the patient was qualified for
second laparotomy. All preoperative results of haema-
tologic and coagulation tests were normal. Total hyste-
rectomy with bilateral salpingo-oophorectomy, omentec-
tomy and anterior resection of the rectum with a low rec-
to-sigmoid anastomosis was carried out.
The operation was completed with an adequate ha-
emostasis with an intraoperative blood loss of about 1000
ml. Two units of packed red blood cells were administered
at the final stage of the operation. Eighteen hours later
the patient became hemodynamically unstable. Postope-
rative blood loss in the abdominal drain reached the level
of 600 ml/h. This was initially managed conservatively
with the infusion of 8 units of packed red blood cells and
4 units of fresh frozen plasma (FFP). As the patient did
not stabilise interventional surgery was performed. Abo-
ut 2000 ml of blood were evacuated from the peritoneal
cavity, while no specific bleeding site was found. A profu-
se oozing from the naked pelvic side walls and floor was
evident. In order to diminish the blood supply to the pe-
lvis a bilateral ligature of the internal iliac artery was per-
formed, with subsequent improvement of vital hemodyna-
mic parameters. Additional supplementation of 8 units of
packed red blood cells, 4 units of FFP and 2 units of pla-
telets was given. Despite blood volume supplementation
and administration of desmopressin (0.4 µg/kg) blood
loss in the abdominal drain was 200 ml/h with simultane-
ous deterioration of the patient's general condition. She
received the first dose of NovoSeven of 20 µg/kg. PT value
fell from 30.2 to 21.3 s and APTT from 85.4 to 48.8 s and
drain blood loss to 35-40 ml/h. The second dose of
NovoSeven of 20 µg/kg was administered 12 h later.
A cessation of bleeding was observed with further im-
provement of PT to12.3 s and APTT to 34.3 s. The results
of principal blood coagulation tests before and after admi-
nistration of NovoSeven are presented in Table I.
Table I. Evolution of principal coagulation parameters after admini-
stration of rVIIa
PLT PT INR APTT D-dimer
1000/ml s s ng/ml
before primary
surgery 111 11.5 0.99 28.6 –
before I dose
of rVIIa 27 30.2 2.41 85.4 437
after I dose
of rVIIa 59 21.3 1.09 48.8 438
after II dose
of rVIIa (48h) 101 12.3 1.43 34.3 205
The subsequent postoperative recovery was unevent-
ful and the patient was discharged from the hospital on
the 11th postoperative day. Five weeks after surgery she
received her next cycle of CAP chemotherapy.
Discussion
Surgery plays a principal role in the diagnosis, staging
and treatment of ovarian cancer. The aim of cytoreducti-
ve surgery is to remove both the primary lesions of the
ovary and other intra-peritoneal implants. In advanced
ovarian cancer removal of bulky tumour masses may im-
prove patient's comfort, reduce the adverse metabolic
consequences of the tumour, increase the ability to tolera-
te intensive chemotherapy and, above all else, improve su-
rvival.
Despite surgical technique improvements cytoreduc-
tive operations lead inevitably to tissue damage with libe-
ration of clot-promoting agents into the circulatory sys-
tem, initiating pathologic coagulation. Endothelial da-
mage at the site of bleeding is associated with an
increased tissue factor (TF) expression, which binds to
the circulating factor VII, resulting in its activation and
the formation of TF-FVIIa complexes. They, in turn, ac-
tivate the coagulation cascade.
From a spectrum of coagulation abnormalities as-
sociated with solid tumours DIC is the most frequently
diagnosed coagulopathy. Overt DIC with rapid consump-
tion of platelets and clotting factors and acute bleeding is
an emergency, which requires immediate transfusion of
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blood, plasma, cryoprecipitate or platelet concentrates.
This traditional method of management of DIC is not
always effective while the infusion of a large volume of
blood products carries the risk of transmitting infectious
diseases. The introduction of recombinant activated fac-
tor VII (NovoSeven) has offered a significant advance-
ment in the management of patients with congenital and
acquired coagulation disorders. Although the principal
indication for rVIIa administration is a deficiency of fac-
tor VII or the inhibitors to factor VIII or IX, there are nu-
merous reports indicating a high effectiveness of
NovoSeven in patients without the primary defects of co-
agulation [6-8]. The unique feature of thrombin genera-
tion at the site of vascular injury after rVIIa administra-
tion has been successfully utilized for the treatment of
acute bleeding complicating cardiovascular, urologic and
brain surgery [6]. There are also a few reports on the suc-
cessful treatment of acute bleeding from locally advanced
endometrial and vaginal cancer [8]. The presented case is
the first description on the effective use of NovoSeven
in the treatment of acute intra-abdominal bleeding with
DIC complicating surgery for advanced ovarian cancer.
The satisfactory clinical effect had been achieved after
two doses of rVIIa of 20 µg/kg each. The optimal dosage
of NovoSeven is a subject of intensive clinical investiga-
tion. Doses between 20 and 90 µg/kg are recommended
for emergencies [4]. There are some controversies regar-
ding the optimal mode of administration of NovoSeven.
A single or repeated bolus injection seems to be as effec-
tive as continuous infusion, and more cost-effective [7].
Prophylaxis of excessive blood loss during radical surgery
is another potential application of NovoSeven.
Preliminary results of a randomized trial comparing
an intra- and postoperative blood loss of patients under-
going radical prostatectomy showed a significant reduc-
tion of blood loss in patients who had received a prophy-
lactic dose of NovoSeven [9].
This trial will be continued to include more patients
before the final conclusions are made.
To summarise – we believe that recombinant FVIIa
may be an effective treatment of severe intra-abdominal
haemorrhage of patients without inherited coagulation
disorders when classic methods of treatment are ineffec-
tive.
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